XML 144 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Segmentation of key figures (Details 1) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of operating segments [line items]      
Net sales to third parties $ 50,545 $ 51,626 $ 48,659
Net sales 50,545 51,626 48,659
Other revenues 1,283 1,251 1,239
Cost of goods sold (15,486) (15,867) (15,121)
Gross profit 36,342 37,010 34,777
Selling, general and administration (14,253) (14,886) (14,197)
Research and development (9,996) (9,540) (8,980)
Other income 805 1,852 1,742
Other expense (3,701) (2,747) (3,190)
Operating income 9,197 11,689 10,152
(Loss)/income from associated companies (9) 15,339 673
Interest expense (837) (811) (869)
Other financial income and expense 20 (80) (78)
Income before taxes 8,371 26,137 9,878
Income taxes (1,416) (2,119) (1,807)
Net income 6,955 24,018 8,071
Attributable to      
Shareholders of Novartis AG 6,955 24,021 8,072
Non-controlling interests 0 (3) (1)
Innovative Medicines      
Disclosure of operating segments [line items]      
Net sales to third parties 41,296 41,995 39,013
Sales to other segments 825 795 792
Net sales 42,121 42,790 39,805
Other revenues 1,249 1,179 1,018
Cost of goods sold (11,569) (11,751) (10,927)
Gross profit 31,801 32,218 29,896
Selling, general and administration (11,679) (12,306) (11,657)
Research and development (9,172) (8,641) (8,118)
Other income 531 1,149 922
Other expense (2,695) (1,732) (1,871)
Operating income 8,786 10,688 9,172
(Loss)/income from associated companies (2) 5 1
Sandoz      
Disclosure of operating segments [line items]      
Net sales to third parties 9,249 9,631 9,646
Sales to other segments 205 180 189
Net sales 9,454 9,811 9,835
Other revenues 28 61 53
Cost of goods sold (4,978) (5,147) (5,252)
Gross profit 4,504 4,725 4,636
Selling, general and administration (2,062) (2,062) (2,076)
Research and development (824) (899) (862)
Other income 103 233 176
Other expense (273) (397) (831)
Operating income 1,448 1,600 1,043
(Loss)/income from associated companies 2 2 2
Corporate      
Disclosure of operating segments [line items]      
Sales to other segments (1,030) (975) (981)
Net sales (1,030) (975) (981)
Other revenues 6 11 168
Cost of goods sold 1,061 1,031 1,058
Gross profit 37 67 245
Selling, general and administration (512) (518) (464)
Other income 171 470 644
Other expense (733) (618) (488)
Operating income (1,037) (599) (63)
(Loss)/income from associated companies $ (9) $ 15,332 $ 670